Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center Hospital for Special Surgery, New York |
---|---|
Information provided by: | Memorial Sloan-Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00580385 |
The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work.
Condition | Intervention |
---|---|
Osteosarcoma |
Biological: Tissue Procurement |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Official Title: | Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors |
Estimated Enrollment: | 500 |
Study Start Date: | August 1997 |
Estimated Study Completion Date: | August 2010 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Biological: Tissue Procurement
MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
|
When tumor tissue known or presumed to be a primary or secondary bone cancer or solid tumor with known elevated intra-tumoral pressure such as retinoblastoma is being removed for diagnostic or therapeutic reasons a small sample of it will be obtained for this study. The tumor samples will be used to study in vitro, determinants of chemotherapy resistance and oncogenesis. These determinants will be correlated with histologic response to preoperative chemotherapy and clinical outcome (event free survival).
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: John Healey, MD | healeyj@mskcc.org |
United States, New York | |
Memorial Sloan-Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 |
Principal Investigator: | John Healey, MD | Memorial Sloan-Kettering Cancer Center |
Responsible Party: | Memorial Sloan-Kettering Cancer Center ( John Healey, MD ) |
Study ID Numbers: | 97-094 |
Study First Received: | December 20, 2007 |
Last Updated: | April 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00580385 History of Changes |
Health Authority: | United States: Food and Drug Administration |
BONE |
Neoplasms, Connective and Soft Tissue Soft Tissue Sarcomas Malignant Mesenchymal Tumor |
Sarcoma Osteogenic Sarcoma Osteosarcoma |
Neoplasms, Connective and Soft Tissue Neoplasms Neoplasms by Histologic Type Neoplasms, Bone Tissue |
Sarcoma Osteosarcoma Neoplasms, Connective Tissue |